SCHEMBL6384666

SCHEMBL6384666

COC(=O)C(Cc1cccc(O)c1)C(=O)OC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NLRP3 Q96P20 1/20 0.51
SPR P35270 1/20 0.49
PPARG P37231 3/20 0.48
PPARD Q03181 2/20 0.48
PPARA Q07869 2/20 0.48
PTPRB P23467 1/20 0.47
EGFR P00533 1/20 0.45
GRIA2 P42262 1/20 0.44
GABRA1 P14867 1/20 0.44
GABRG2 P18507 1/20 0.44
GABRB3 P28472 1/20 0.44
GABRA3 P34903 1/20 0.44
GABRA2 P47869 1/20 0.44
GABRB2 P47870 1/20 0.44
ESR1 P03372 1/20 0.44
ESR2 Q92731 1/20 0.44
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
PKM P14618 1/20 0.43
ALOX15 P16050 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2564195 0.92 NLRP3 (0.48) NLRP3SPRPPARGPPARDPPARA
SCHEMBL6536326 0.85 NOS2 (0.42) NLRP3SPRPPARGPPARDPPARA
SCHEMBL2500604 0.85 NLRP3 (0.50) NLRP3SPREGFRGRIA2GABRA1
SCHEMBL13085683 0.85 NLRP3 (0.50) NLRP3SPREGFRGRIA2GABRA1
SCHEMBL27810401 0.85 NLRP3 (0.50) NLRP3SPREGFRGRIA2GABRA1
SCHEMBL27705535 0.85 NLRP3 (0.50) NLRP3SPREGFRGRIA2GABRA1
SCHEMBL2496147 0.85 NLRP3 (0.50) NLRP3SPREGFRGRIA2GABRA1
SCHEMBL1816260 0.84 GRIA2 (0.56) NLRP3SPRGRIA2CYP1A2CYP3A4
SCHEMBL5360127 0.84 NLRP3 (0.49) NLRP3SPREGFRGRIA2GABRA1
SCHEMBL2580149 0.84 GRIA2 (0.56) NLRP3SPRGRIA2CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050032787-A1 Pheny (alkyl)carboxylic acid derivatives and dionic phenylalkylheterocyclic derivatives and their use as medicines with serum glucose and/or serum lipid lowering activity SIGMA-TAU INDUSTRIES FARMACEUTICHE RIUNITE S.P.A. (IT) 2005-02-10 US disclosed
EP-1465858-A2 PHENY(ALKYL)CARBOXYLIC ACID DERIVATIVES AND DIONIC PHENYLALKYLHETEROCYCLIC DERIVATIVES AND THEIR USE AS MEDICINES WITH SERUM GLUCOSE AND/OR SERUM LIPID LOWERING ACTIVITY Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) 2004-10-13 EP disclosed
WO-2003059864-A2 PHENY(ALKYL)CARBOXYLIC ACID DERIVATIVES AND DIONIC PHENYLALKYLHETEROCYCLIC DERIVATIVES AND THEIR USE AS MEDICINES WITH SERUM GLUCOSE AND/OR SERUM LIPID LOWERING ACTIVITY SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2003-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032787-A1 Pheny (alkyl)carboxylic acid derivatives and dionic phenylalkylheterocyclic derivatives and their use as medicines with serum glucose and/or serum lipid lowering activity LIPC, CPT1A, GPR119 NLRP3 2139/4885SPR 2949/4885PPARG 127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.